Alexandria, Virginia, September 30,2024
The National Psoriasis Foundation (NPF) is proud to announce its support of CorEvitas’ new independent clinical registry in generalized pustular psoriasis (GPP). The GPP registry collects health data from dermatology clinical practices to address an unmet need for real-world evidence related to the clinical and patient-reported outcomes of patients with GPP. Data will be collected regarding safety and effectiveness of approved advanced and standard-of-care therapies, as well as treatment patterns.
CorEvitas, which is part of Thermo Fisher Scientific Inc., the world leader in serving science, launched the registry in March. Now, NPF is going to collaborate with CorEvitas within Thermo Fisher’s PPD™ clinical research business to help promote the visibility of this new registry with the aim of increasing overall awareness and participation.
GPP is a rare disease that affects approximately one of every 10,000 people in the United States. Untreated flares can be accompanied by severe complications, and, if left untreated, these complications can be life-threatening.
Established under the leadership of NPF medical board members Mark Lebwohl, M.D., dean for clinical therapeutics, Icahn School of Medicine at Mount Sinai, and Bruce Strober, M.D., clinical professor, Department of Dermatology at Yale University, the registry aims to be one of the largest science-driven GPP registries in North America.
The registry is enrolling patients who have a diagnosis of GPP, are at least 18 years of age, and are willing to provide a limited set of health data. Individuals do not need to be on any specific treatment or be actively flaring to be enrolled. They can be enrolled into the registry any time they are determined to be eligible.
“Since GPP is a rare disease with severe complications, it is critical that NPF enlist its community of patients and health care providers to participate in this important CorEvitas registry,” said Guy Eakin, Ph.D., the Chief Scientific and Medical Officer of NPF. “As participating sites, health care providers are actively contributing to our understanding of GPP, which we hope will lead to improved treatments and therapy options for future patients.”
“Each patient is critically important to the GPP registry,” said Leah M. Howard, J.D., President and CEO of NPF. “Because of the rarity of the disease, joining the registry helps create new information about GPP. We hope that individuals living with GPP will join the registry so that we can work together to find better treatments for everyone living with this rare disease.”
If you are a health care provider interested in becoming a site, email psoriasis@corevitas.com.
If you are living with GPP and interested in participating in this registry, talk to your dermatology provider and encourage them to reach out to NPF (getinfo@psoriasis.org) or CorEvitas (psoriasis@corevitas.com) to learn more.
About the National Psoriasis Foundation
The National Psoriasis Foundation has served the community of people impacted by psoriatic disease since 1967 with patient support, advocacy, research, and education. The mission of NPF is to drive efforts to cure psoriatic disease and improve the lives of more than 8 million individuals in the United States affected by this chronic immune-mediated disease. Learn more at psoriasis.org.